Get the Stockscreener App
19.37
1.53%
-0.30
After Hours:
19.45
0.08
+0.41%
Arrowhead Pharmaceuticals Inc stock is traded at $19.37, with a volume of 1.77M.
It is down -1.53% in the last 24 hours and down -18.72% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$19.67
Open:
$19.33
24h Volume:
1.77M
Relative Volume:
1.77
Market Cap:
$2.39B
Revenue:
$181.74M
Net Income/Loss:
$-296.81M
P/E Ratio:
-11.33
EPS:
-1.71
Net Cash Flow:
$-402.70M
1W Performance:
-3.15%
1M Performance:
-18.72%
6M Performance:
-32.27%
1Y Performance:
-27.91%
1-Day Range:
$19.10
$19.76
1-Week Range:
$19.07
$20.55
52-Week Range:
$19.07
$39.83
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Severe Hypertriglyceridemia Market Growth to Accelerate - openPR
Severe Hypertriglyceridemia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Ionis Pharma, 89bio, Inc., Arrowhead Pharma, Hightide Therapeutics, AstraZeneca, Kowa - Barchart
383,826 Shares in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Bought by Squarepoint Ops LLC - MarketBeat
(ARWR) Investment Analysis and Advice - Stock Traders Daily
Wall Street SWOT: Arrowhead Pharmaceuticals stocksiRNA pioneer targets metabolic diseases - Investing.com Canada
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Outperform Rating at Royal Bank of Canada - MarketBeat
Arrowhead stock touches 52-week low at $19.43 amid market shifts - Investing.com Canada
Affinity Asset Advisors LLC Reduces Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand - Clinical Trials Arena
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand - Yahoo Finance
With 73% ownership of the shares, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is heavily dominated by institutional owners - Yahoo Finance
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - BioSpace
Avoro Capital Advisors LLC Has $231.02 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - StockTitan
Seven Eight Capital LP Sells 40,663 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 12-Month Low at $20.04 - MarketBeat
(ARWR) Trading Signals - Stock Traders Daily
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Sees Significant Decline in Short Interest - MarketBeat
TD Asset Management Inc Increases Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Trading Up 7.6% - MarketBeat
Arrowhead Pharmaceuticals’ Plozasiran Receives Breakthrough Therapy Designation from the FDA - European Pharmaceutical Manufacturer
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year Low at $20.63 - MarketBeat
FDA grants breakthrough therapy status to Arrowhead’s plozasiran - Pharmaceutical Technology
Arrowhead Pharmaceuticals Becomes Oversold (ARWR) - Nasdaq
ARWR: PALISADE Phase 3 Results Published in NEJM… - Zacks Small Cap Research
ARWR: PALISADE Phase 3 Results Published in NEJM - Research Tree
ARWR: PALISADE Phase 3 Results Published in NEJM… - Yahoo Finance
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran - Morningstar
Arrowhead Pharmaceuticals Gets FDA Breakthrough Designation for Plozasiran - MarketWatch
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - The Bakersfield Californian
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat
Interesting ARWR Put And Call Options For October 18th - Nasdaq
FY2024 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Decreased by HC Wainwright (NASDAQ:ARWR) - MarketBeat
Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) PT at $44.25 - MarketBeat
Principal Financial Group Inc. Sells 59,354 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
The past three years for Arrowhead Pharmaceuticals (NASDAQ:ARWR) investors has not been profitable - Simply Wall St
Brokers Set Expectations for Arrowhead Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ARWR) - MarketBeat
FY2025 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Raised by Leerink Partnrs (NASDAQ:ARWR) - MarketBeat
Bank of New York Mellon Corp Has $28.20 Million Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - MSN
Arrowhead Pharmaceuticals’ (ARWR) Buy Rating Reaffirmed at HC Wainwright - Defense World
Arrowhead chases Ionis in rare, genetic disease race - BioWorld Online
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Buy Rating at HC Wainwright - MarketBeat
Arrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New Drug - Yahoo Finance
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints - Yahoo Finance
Arrowhead to file NDA after pivotal rare disease trial meets all endpoints - Clinical Trials Arena
Arrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for Plozasiran - MarketWatch
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome - Business Wire
When the Price of (ARWR) Talks, People Listen - Stock Traders Daily
Arrowhead Teeing Up Drug Trials - Los Angeles Business Journal
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):